EU Approves Brineura for CLN2 DiseaseApprovals, EMA, European Commission, FDA/Regulatory, First-In-Class, Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), Rare DiseasesThe European Commission granted marketing authorization for BioMarin Pharmaceutical’s Brineura for the treatment of tripeptidyl peptidase 1 (TPP1) deficiency. Read more June 1, 2017/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2017-06-01 08:31:042017-06-01 13:22:05EU Approves Brineura for CLN2 Disease
